Integrated Biopharma, Inc.
INBP
$0.32
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.82% | 11.21% | 6.09% | 9.60% | 5.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.82% | 11.21% | 6.09% | 9.60% | 5.44% |
| Cost of Revenue | -4.70% | 10.85% | 4.18% | 4.13% | 1.35% |
| Gross Profit | -25.67% | 14.41% | 24.28% | 125.19% | 64.78% |
| SG&A Expenses | -2.84% | -0.23% | -9.07% | -0.31% | -0.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.58% | 10.06% | 3.25% | 3.77% | 1.22% |
| Operating Income | -66.73% | 46.52% | 108.17% | 144.69% | 1,007.41% |
| Income Before Tax | -61.11% | 43.72% | 121.02% | 140.93% | 1,195.65% |
| Income Tax Expenses | -70.20% | 429.45% | 149.25% | 198.57% | 1,784.62% |
| Earnings from Continuing Operations | -52.51% | -166.42% | 114.39% | 130.37% | 538.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.51% | -166.42% | 114.39% | 130.37% | 538.98% |
| EBIT | -66.73% | 46.52% | 108.17% | 144.69% | 1,007.41% |
| EBITDA | -58.26% | 38.36% | 88.66% | 176.20% | 2,400.00% |
| EPS Basic | -53.49% | -165.17% | 112.63% | 129.92% | 530.00% |
| Normalized Basic EPS | -62.86% | 43.02% | 109.59% | 147.31% | 1,150.00% |
| EPS Diluted | -54.65% | -165.17% | 110.53% | 129.13% | 530.00% |
| Normalized Diluted EPS | -62.14% | 46.43% | 108.45% | 146.24% | 1,130.00% |
| Average Basic Shares Outstanding | 3.19% | 1.70% | 0.67% | 0.25% | 0.45% |
| Average Diluted Shares Outstanding | 2.52% | -0.30% | 2.51% | 4.00% | 2.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |